BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
10.10
-0.17 (-1.66%)
May 7, 2025, 12:04 PM EDT - Market open
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $145.53M in the quarter ending March 31, 2025, with 56.89% growth. This brings the company's revenue in the last twelve months to $503.49M, up 41.67% year-over-year. In the year 2024, BioCryst Pharmaceuticals had annual revenue of $450.71M with 36.00% growth.
Revenue (ttm)
$503.49M
Revenue Growth
+41.67%
P/S Ratio
4.23
Revenue / Employee
$868,078
Employees
580
Market Cap
2.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BCRX News
- 1 day ago - BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors - Benzinga
- 1 day ago - BioCryst: Strong Opportunity For A Double With A Proven Therapy - Seeking Alpha
- 1 day ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - BioCryst Appoints Steve Frank to Board of Directors - GlobeNewsWire
- 7 days ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - BioCryst to Report First Quarter 2025 Financial Results on May 5 - GlobeNewsWire